RT Journal Article
SR Electronic
T1 Effect of Nirmatrelvir/Ritonavir (Paxlovid) on Hospitalization among Adults with COVID-19: an EHR-based Target Trial Emulation from N3C
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.03.23289084
DO 10.1101/2023.05.03.23289084
A1 Bhatia, Abhishek
A1 Preiss, Alexander J.
A1 Xiao, Xuya
A1 Brannock, M. Daniel
A1 Alexander, G. Caleb
A1 Chew, Robert F.
A1 Fitzgerald, Megan
A1 Hill, Elaine
A1 Kelly, Elizabeth P.
A1 Mehta, Hemalkumar B.
A1 Madlock-Brown, Charisse
A1 Wilkins, Kenneth J.
A1 Chute, Christopher G.
A1 Haendel, Melissa
A1 Moffitt, Richard
A1 Pfaff, Emily R.
A1 The N3C Consortium
YR 2023
UL http://medrxiv.org/content/early/2023/05/04/2023.05.03.23289084.abstract
AB This study leverages electronic health record data in the National COVID Cohort Collaborative’s (N3C) repository to investigate disparities in Paxlovid treatment and to emulate a target trial assessing its effectiveness in reducing COVID-19 hospitalization rates. From an eligible population of 632,822 COVID-19 patients seen at 33 clinical sites across the United States between December 23, 2021 and December 31, 2022, patients were matched across observed treatment groups, yielding an analytical sample of 410,642 patients. We estimate a 65% reduced odds of hospitalization among Paxlovid-treated patients within a 28-day follow-up period, and this effect did not vary by patient vaccination status. Notably, we observe disparities in Paxlovid treatment, with lower rates among Black and Hispanic or Latino patients, and within socially vulnerable communities. Ours is the largest study of Paxlovid’s real-world effectiveness to date, and our primary findings are consistent with previous randomized control trials and real-world studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe analyses described in this publication were conducted with data or tools accessed through the NCATS N3C Data Enclave (covid.cd2h.org/enclave) and supported by CD2H - The National COVID Cohort Collaborative (N3C) IDeA CTR Collaboration 3U24TR002306-04S2 NCATS U24 TR002306.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The N3C data transfer to NCATS is performed under a Johns Hopkins University Reliance Protocol # IRB00249128 or individual site agreements with NIH. The work was performed under DUR RP-5677B5.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data is available in the N3C Data Enclave to those with an approved protocol and data use request from an institutional review board. Data access is governed under the authority of the National Institutes of Health; more information on accessing the data can be found at https://covid.cd2h.org/for-researchers. See Haendel et. al. for additional detail on how data is ingested, managed, and protected within the N3C Data Enclave.